M&A Deal Summary

Miravo Healthcare Acquires Aralez Pharmaceuticals - VIMOVO Royalties

On August 10, 2018, Miravo Healthcare acquired life science company Aralez Pharmaceuticals - VIMOVO Royalties from Aralez Pharmaceuticals for 110M USD

Acquisition Highlights
  • This is Miravo Healthcare’s 2nd transaction in the Life Science sector.
  • This is Miravo Healthcare’s 3rd largest (disclosed) transaction.
  • This is Miravo Healthcare’s 2nd transaction in Canada.
  • This is Miravo Healthcare’s 2nd transaction in Ontario.

M&A Deal Summary

Date 2018-08-10
Target Aralez Pharmaceuticals - VIMOVO Royalties
Sector Life Science
Buyer(s) Miravo Healthcare
Sellers(s) Aralez Pharmaceuticals
Deal Type Divestiture
Deal Value 110M USD

Target

Aralez Pharmaceuticals - VIMOVO Royalties

Milton, Ontario, Canada
website
Aralez Pharmaceuticals, Inc. - VIMOVO Royalties is a provider of biotechnological services in Milton, Canada.

Search 193,605 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Miravo Healthcare

Mississauga, Ontario, Canada

website


Category Company
Founded 1983
Sector Healthcare Services
Employees100
Revenue 69M CAD (2021)
DESCRIPTION

Miravo Healthcare is a specialty pharmaceutical company with a diverse portfolio of products and technologies. Miravo Healthcare was founded in 1983 and is based in Mississauga, Canada.


DEAL STATS #
Overall 2 of 3
Sector (Life Science) 2 of 3
Type (Divestiture) 1 of 2
State (Ontario) 2 of 3
Country (Canada) 2 of 3
Year (2018) 2 of 3
Size (of disclosed) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-08-10 Aralez Pharmaceuticals

Milton, Ontario, Canada

Aralez Pharmaceuticals is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while focusing on creating shareholder value by acquiring, developing, and commercializing products primarily in cardiovascular, pain, and other specialty areas. Aralez Pharmaceuticals was founded in 2015 and is based in Mississauga, Canada.

Buy $110M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-09-19 Aralez Pharmaceuticals - Commercial Products & Infrastructure Pharmaceutical Business

Milton, Ontario, Canada

Aralez Pharmaceuticals, Inc. - Commercial Products & Infrastructure Pharmaceutical Business is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products.

Buy $110M

Seller(S) 1

SELLER

Aralez Pharmaceuticals

Milton, Ontario, Canada

website


Category Company
Founded 2015
Sector Life Science
Employees164
Revenue 106M USD (2017)
DESCRIPTION

Aralez Pharmaceuticals is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while focusing on creating shareholder value by acquiring, developing, and commercializing products primarily in cardiovascular, pain, and other specialty areas. Aralez Pharmaceuticals was founded in 2015 and is based in Mississauga, Canada.


DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Divestiture) 1 of 2
State (Ontario) 1 of 2
Country (Canada) 1 of 2
Year (2018) 1 of 2
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-10-04 AstraZeneca - Toprol-XL

London, United Kingdom

AstraZeneca Plc - Toprol-XL is a provider of treatment of high blood pressure. By lowering blood pressure, Toprol-XL may lower the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Toprol-XL is also indicated for the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance and for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, Toprol-XL decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure.

Buy $175M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-09-19 Aralez Pharmaceuticals - Commercial Products & Infrastructure Pharmaceutical Business

Milton, Ontario, Canada

Aralez Pharmaceuticals, Inc. - Commercial Products & Infrastructure Pharmaceutical Business is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products.

Sell $110M